Astrazeneca (AZN) Stock Moves -0.39%: What You Should Know

Yahoo Finance18:15 ET

Daiichi Sankyo Gets Japanese Approval for Datroway

Seeking AlphaDec 27 10:52 ET

Here's Why Astrazeneca (AZN) Is a Strong Value Stock

Yahoo FinanceDec 27 09:40 ET

Syncona: Achilles Announces Sale Of Technology Assets To AstraZeneca - Quick Facts

RTTNewsDec 27 02:12 ET

Achilles Therapeutics Sells Key Assets to AstraZeneca

TipRanksDec 27 02:08 ET

Orient: Initiated a "Buy" rating for Hutchmed (China) with a Target Price of HKD 33.24.

Orient issued a research report predicting that Hutchmed (China) (00013) will have revenue of 680 million, 844 million, and 1 billion USD for 2024-2026, respectively. Based on comparable companies, a 4.4 times PS is given for the company in 2025, corresponding to a Target Price of 33.24 HKD, with an initial 'Buy' rating. Orient's main points are as follows: a Global layout of small molecule Innovative Drugs. The company was founded in 2000, and after more than twenty years of deep cultivation in the small molecule oncology field, it has three commercialized products and several late-stage clinical drugs, accumulating rich experience in commercial Operation, and partnering with...

Sina Hong Kong StockDec 26 21:27 ET